9 in 10 Heavily Treated CTCL Patients See Benefits with IPH4102, Phase 1 Trial Shows
News
IPH4102, Innate Pharma’s investigational antibody, reduced tumor volume in 36% of patients with cutaneous T-cell lymphoma (CTCL) in a Phase 1 trial. Patients were heavily pre-treated, having received at least two ... Read more